MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth

MitoRx Therapeutics announces the appointment of Alison Strutt as Chief Financial Officer, László Tankó as Consultant Chief Medical Officer, and Sam Fazeli as Non-Executive Director. These appointments support the company's advancement of MTRX31, a first-in-class small molecule therapy for metabolically unhealthy obesity, towards clinical development following promising preclinical data.